LIAONING CHENGDA BIOTECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.49 CNY | +0.14% |
|
+0.11% | -12.37% |
| May. 20 | Wall Street Cues, Central Bank Outlooks Lift Asian Stock Markets | MT |
| Apr. 29 | Liaoning Chengda Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on Liaoning Chengda Biotechnology Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.49% | - |
Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research, production, and sales of human vaccines. The Company's main products include rabies vaccine for human use, freeze-dried rabies vaccine for human use, inactivated Japanese encephalitis vaccine for human use and freeze-dried encephalitis inactivated vaccine. The Company's products include two brands: Chengda Suda and Chengda Libao.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
28.49
CNY
Average target price
32
CNY
Spread / Average Target
+12.32%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.37% | 1.63B | |
| -3.15% | 89.69B | |
| +3.95% | 41.34B | |
| -10.51% | 33.72B | |
| +59.00% | 26.11B | |
| -20.09% | 14.63B | |
| -8.92% | 12.84B | |
| -11.46% | 11.66B | |
| -43.05% | 11.52B | |
| +6.07% | 8.92B |
- Stock Market
- Equities
- 688739 Stock
- Funds and ETFs Liaoning Chengda Biotechnology Co.,Ltd.